Co-delivery of ampicillin and β-lactamase inhibitor by selenium nanocomposite to achieve synergistic anti-infective efficiency through overcoming multidrug resistance

Zekun Wang,Pu Zhang,Xiaoyuan Ding,Jingyuan Wang,Yu Sun,Chenyang Yin,Weiyun Wang,Cundong Fan,Dongdong Sun
DOI: https://doi.org/10.1016/j.cej.2021.128908
IF: 15.1
2021-06-01
Chemical Engineering Journal
Abstract:<p>Bacterial infective diseases due to antibiotic resistance remain a great challenge in clinic. Design of novel antibacterial drugs with high efficiency and low side effects to overcome antibiotic resistance is urgently needed. Herein, M-Cs (mannose- modified chitosan) modified selenium (Se) nanoparticles to co-deliver ampicillin (Ap) and <em>β</em>-lactamase inhibitor were synthesized and characterized (SAMCP NPs). Mannose modification endowed SAMCP NPs with enhanced recognition of bacteria by FimH lectin. Co-delivery of ampicillin and <em>β</em>-lactamase inhibitor (3-carboxyphenylboronic acid, Pba) by selenium nanocomposite (30 μg/mL) effectively inhibited <em>β</em>-lactamase activity, which synergistically enhanced ampicillin-induced antibacterial activity against ampicillin-resistant <em>Escherichia coli (E. coli <sup>(R)</sup>) in vitro</em> by suppression of AcrAB-TolC efflux pump system through eliminating ROS. SAMCP NPs (5 mg/kg) <em>in vivo</em> also showed synergistic anti-infective efficiency by inhibiting <em>E. coli <sup>(R)</sup></em> infection-induced inflammatory response, cell apoptosis and regulating multiple signal pathways, and eventually promoted wound healing of mice. Importantly, SAMCP NPs displayed low toxicity and low side effects <em>in vivo</em>. Our findings validated our rational design that co-delivery of ampicillin and <em>β</em>-lactamase inhibitor by selenium nanocomposite to overcome multidrug resistance could be a highly efficient way to achieve antibacterial synergy.</p>
engineering, chemical, environmental
What problem does this paper attempt to address?